Ondine Biomedical Inc. (LON:OBI) Insider Acquires £19,399.25 in Stock

Ondine Biomedical Inc. (LON:OBI) insider Carolyn Cross acquired 149,225 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were acquired at an average cost of GBX 13 ($0.16) per share, with a total value of £19,399.25 ($24,134.42).

Carolyn Cross also recently made the following trade(s):

• On Thursday, January 30th, Carolyn Cross acquired 200,775 shares of Ondine Biomedical stock. The shares were bought at an average price of GBX 12 ($0.15) per share, with a total value of £24,093 ($29,973.87).

Ondine Biomedical Stock Performance

Shares of OBI stock opened at GBX 12.55 ($0.16) on Tuesday. The firm has a market capitalization of £34.80 million, a price-to-earnings ratio of -418.33 and a beta of 0.10. The company has a debt-to-equity ratio of 1,847.37, a current ratio of 0.80 and a quick ratio of 8.26. Ondine Biomedical Inc. has a 12-month low of GBX 4.50 ($0.06) and a 12-month high of GBX 13.30 ($0.17). The business has a 50 day simple moving average of GBX 9.25 and a 200 day simple moving average of GBX 8.01.

About Ondine Biomedical

Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens.

Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings.